Key result
Beta-blocker use in elderly hypertensive patients was associated with an increased risk for cardiovascular events compared with other antihypertensive therapies (OR 1.36; 95% CI 1.31-1.40).
Why the study?
Do antihypertensive therapies that include beta-blockers increase the risk of first cardiovascular events compared to therapies without beta-blockers in elderly primary prevention patients with uncomplicated hypertension?
Case-Control (n=94,844)
Do antihypertensive therapies that include beta-blockers increase the risk of first cardiovascular events compared to therapies without beta-blockers in elderly primary prevention patients with uncomplicated hypertension?
In elderly patients with uncomplicated hypertension, the use of beta-blockers for primary prevention is associated with a significantly increased risk of first cardiovascular events compared to other antihypertensive agents.
May warrant caution with beta-blockers in elderly hypertensives; hypothesis-generating pending randomized confirmation.
PURPOSE: Although treatment should be considered for elderly patients with hypertension (HTN), the effectiveness of beta-blockers (BBs) compared with other medications is less clear. This study's objective is to assess the relative effectiveness of BBs in elderly primary prevention patients with uncomplicated HTN. METHODS: This is a population-based nested case-control study. The cohort is composed of 94,844 elderly patients followed through 2009 and diagnosed with HTN between 2000 and 2004, without recent antecedents of diabetes, renal disease, or cardiovascular disease (CVD). Individuals with a CVD outcome were considered cases, and controls were matched to cases according to age, sex, date of cohort entry, and comorbidity index. Patients whose treatment included a BB were compared with patients on other HTN drug(s). RESULTS: The BB use by patients was associated with an increased risk for CVD events (odds ratio (OR) = 1.36, 95%CI: 1.31-1.40) compared with patients using antihypertensive therapies without BBs. Sensitivity analyses suggest that this increased risk is not due to differences in prescription patterns on the basis of perceived disease severity. CONCLUSIONS: In real-world settings, antihypertensive therapies that include BBs are associated with less effective prevention of adverse outcomes in elderly hypertensive patients in primary prevention compared with antihypertensive therapies without BBs. Pending further studies, we recommend caution when prescribing BBs in primary prevention except when otherwise indicated.
No takes yet. Share an insight, caveat, or question.
Brouwers et al. (2014) conducted a case-control in Hypertension (n=94,844). Beta-blockers vs. Antihypertensive therapies without beta-blockers was evaluated on Cardiovascular events (OR 1.36, 95% CI 1.31-1.40). Beta-blocker use in elderly hypertensive patients was associated with an increased risk for cardiovascular events compared with other antihypertensive therapies (OR 1.36; 95% CI 1.31-1.40).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: